Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:183097.
doi: 10.1155/2010/183097. Epub 2010 Jun 2.

Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine

Jakob Kljun  1 , Sasa Petricek, Dusan Zigon, Rosana Hudej, Damijan Miklavcic, Iztok Turel
Affiliations

Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine

Jakob Kljun et al. Bioinorg Chem Appl. 2010.

Abstract

Novel ruthenium(III) complexes with histamine [RuCl(4)(dmso-S)(histamineH)] . H( (2) )O (1a) and [RuCl(4)(dmso-S)(histamineH)] (1b) have been prepared and characterized by X-ray structure analysis. Their crystal structures are similar and show a protonated amino group on the side chain of the ligand which is not very common for a simple heterocyclic derivative such as histamine. Biological assays to test the cytotoxicity of the compound 1b combined with electroporation were performed to determine its potential for future medical applications in cancer treatment.

PubMed Disclaimer

Figures

Scheme 1
Scheme 1
NAMI-A and KP1019.
Scheme 2
Scheme 2
Histamine.
Scheme 3
Scheme 3
Two step synthesis and structure of the novel ruthenium complex with histamine.
Figure 1
Figure 1
Asymmetric unit of the crystal structure of complex 1b. The ellipsoids are shown at 50% probability.
Figure 2
Figure 2
The hydrogen bonds in the crystal structure of compound 1b. The ammonioethyl groups of the lower two asymmetric units are omitted for clarity.
Figure 3
Figure 3
The packing in the crystal structure of compound 1a along the z axis.
See this image and copyright information in PMC

References

    1. Wiltshaw E. Cisplatin in the treatment of cancer: the first metal anti-tumour drug. Platinum Metals Review. 1979;23(3):90–98.
    1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer. 2007;7(8):573–584. - PubMed
    1. Hambley TW. Developing new metal-based therapeutics: challenges and opportunities. Dalton Transactions. 2007;(43):4929–4937. - PubMed
    1. Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Current Topics in Medicinal Chemistry. 2004;4(15):1525–1535. - PubMed
    1. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. From bench to bedside—preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) Journal of Inorganic Biochemistry. 2006;100(5-6):891–904. - PubMed

LinkOut - more resources